Search
-
News
Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology on April 1.
… Thursday, July 1, 2010 Summary Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology on April 1. Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology
-
News
Peripheral neuropathy is a common side effect of many types of chemotherapy. Learn about what it is, why it happens, and how to treat CIPN.
… Tuesday, August 23, 2022 Peripheral neuropathy — a nerve disorder that can cause weakness, numbness, pain, and tingling or a “pins and needles” feeling — is a common side effect of chemotherapy treatment . Sometimes described as “chemo feet” and “chemo hands,” chemotherapy-induced peripheral neuropathy
-
NewsRespuestas a 8 preguntas frecuentes sobre la neuropatía periférica inducida por quimioterapia (CIPN)
La neuropatía periférica es un efecto secundario común de muchos tipos de quimioterapia. Obtenga información sobre qué es, por qué ocurre y cómo tratar la neuropatía periférica inducida por quimioterapia (CIPN).
… Tuesday, August 23, 2022 La neuropatía periférica , un trastorno nervioso que puede causar debilidad, entumecimiento, dolor y hormigueo o una sensación de “pinchazos”, es un efecto secundario común del tratamiento con quimioterapia . A veces descrita como “pies de quimioterapia” y “manos de quimioterapia
-
News
Hear from an MSK social worker about developing body confidence after cancer treatment.
… Wednesday, July 31, 2019 Summary A person’s body image can change during and after cancer treatment. But support is available. One MSK social worker shares common concerns and how people can find healing and hope. Even after the surgery is over, the last chemotherapy infusion has been given, and the
-
News
According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
… Tuesday, July 24, 2007 Steep Learning Curve Found According to a new study published online today in the Journal of the National Cancer Institute , prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by
-
News
In her 21 years at MSK, Tatanisha Peets has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services.
… Tuesday, February 22, 2022 In her 21 years at MSK, Tatanisha Peets has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services. Currently the Patient Experience Manager in Food and Nutrition Services, Tatanisha began her career at MSK as a secretary
-
News
Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.
… Wednesday, July 6, 2016 Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber
-
News
MSK’s SPORE grant in leukemia has the potential to develop practice-changing approaches, evaluation, and management that may lead to improved patient outcomes for AML.
… Tuesday, September 7, 2021 The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone
-
News
Meet Leslie Ballantyne, Vice President of HR Legal and Regulatory Affairs at Memorial Sloan Kettering.
… Friday, April 2, 2021 Leslie Ballantyne says Eleanor Roosevelt has inspired her both personally and professionally. “The breadth of her accomplishments and commitment to her causes is just astounding,” says MSK’s Vice President of HR Legal and Regulatory Affairs. “She was ahead of her time in being an
-
News
A two-drug combination may hold the key to overcoming resistance in an aggressive form of non-Hodgkin lymphoma.
… Friday, November 16, 2018 Summary A promising target in the treatment of diffuse large B cell lymphoma (DLBCL) is a protein called BCL2. Drugs that inhibit this protein have been disappointing so far. Researchers have now discovered why DLBCL often proves resistant to this treatment. They have shown